This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ThermoGenesis Reports Second Quarter Fiscal 2013 Results

Plavan noted publication during the second quarter of encouraging data from the Company's critical limb ischemia (CLI) clinical evaluation of the MXP in Naples. This is a Phase 1 study that used the MXP platform to produce cell concentrate for use in treating peripheral artery disease patients with CLI. "These were patients who were either not a candidate for surgical revascularization or had not benefited from previous revascularization procedures. At 12 months, blood flow for the patient cohort was double that prior to the infusion of the MXP-produced cell concentrate, and 10 of the 13 patients experienced improved blood flow," he noted.

For the first six months of fiscal 2013, ThermoGenesis reported net income of $432,000, or $0.03 per diluted share, compared to a net loss of $2.5 million, or $0.15 per share, in the first six months of 2012. The results for the first six months of 2013 include a gain on sale of $2 million related to the CryoSeal transaction.

Conference Call and Webcast

Management will hold a conference call today at 2 p.m., Pacific (5 p.m., Eastern) to review the second quarter fiscal 2013 results.
Conference call details:  
Dial-in (U.S.): 1-800-860-2442
Dial-in (Internationally): 1-412-858-4600
Conference Name: "ThermoGenesis"

To listen to the audio webcast of the call during or after the event, please visit

An audio replay of the conference call will be available beginning approximately two hours after completion of the call for the following five business days.
To access the replay:  
Access number (U.S.): 1-877-344-7529
Access number (Internationally) 1-412-317-0088
Conference ID#: 385107

About ThermoGenesis Corp.

ThermoGenesis Corp. ( ) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the separation, preservation and delivery of cell and tissue therapy products. These include:
  • The BioArchive ® System, an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.
  • AXP ® AutoXpress ® Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP ® MarrowXpress ® and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. The MXP is used for the preparation of cell concentrates, including stem cells from bone marrow aspirates in the laboratory setting.
  • The Res-Q ® 60 BMC/PRP (Res-Q), a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates and whole blood for platelet rich plasma (PRP).

The ThermoGenesis Corp. logo is available at

This press release contains forward-looking statements. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors including timing of FDA and foreign regulatory approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2013, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2013. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
ThermoGenesis Corp.
Condensed Balance Sheet 
  December, June 30,
  2012 2012
Current assets:    
Cash and cash equivalents $7,516,000 $7,879,000
Accounts receivable, net 5,355,000 4,558,000
Inventories 5,352,000 6,290,000
Prepaid expenses and other current assets 420,000 338,000
Total current assets 18,643,000 19,065,000
Equipment, net 1,712,000 1,652,000
Other assets 287,000 363,000
  $20,642,000 $21,080,000
Current liabilities:    
Accounts payable $1,400,000 $2,772,000
Other current liabilities 2,587,000 2,259,000
Total current liabilities 3,987,000 5,031,000
Long-term liabilities 107,000 151,000
Stockholders' equity 16,548,000 15,898,000
  $20,642,000 $21,080,000
Condensed Consolidated Statements of Operations
  Three Months Ended, Six Months Ended,
  December 31, December 31,
  2012 2011 2012 2011
Net revenues $4,802,000 $4,775,000 $8,924,000 $9,634,000
Cost of revenues 2,826,000 3,071,000 5,322,000 5,931,000
Gross profit 1,976,000 1,704,000 3,602,000 3,703,000
Selling, general and administrative 1,820,000 1,991,000 3,616,000 4,307,000
Research and development 714,000 1,037,000 1,552,000 1,960,000
Gain on sale of product line -- -- (2,000,000) --
Total operating expenses 2,534,000 3,028,000 3,168,000 6,267,000
Interest and other income, net (5,000) 46,000 (2,000) 78,000
Net income (loss) ($563,000) ($1,278,000) $432,000 ($2,486,000)
ThermoGenesis Corp.
Condensed Statements of Cash Flows (Unaudited)
  Six Months Ended,
  December 31,
  2012 2011
Cash flows from operating activities:    
Net income (loss) $432,000 ($2,486,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 266,000 202,000
Stock based compensation expense 272,000 621,000
Loss on disposal of equipment 7,000 --
Gain on sale of product line (2,000,000) --
Net change in operating assets and liabilities:    
Accounts receivable, net (797,000) (1,018,000)
Inventories 710,000 (322,000)
Prepaid expenses and other current assets (82,000) 130,000
Other assets -- 1,000
Accounts payable (1,087,000) (143,000)
Accrued payroll and related expenses (168,000) 40,000
Deferred revenue (135,000) 32,000
Other liabilities 87,000 (156,000)
Net cash used in operating activities (2,495,000) (3,099,000)
Cash flows from investing activities:    
Capital expenditures (314,000) (481,000)
Proceeds from sale of product line 2,000,000 --
Proceeds from prepayment from sale of product line 500,000 --
Net cash provided by (used in) investing activities 2,186,000 (481,000)
Cash flows from financing activities:    
Repurchase of common stock (54,000) --
Net cash used in financing activities (54,000) --
Net decrease in cash and cash equivalents (363,000) (3,580,000)
Cash and cash equivalents at beginning of period 7,879,000 12,309,000
Cash and cash equivalents at end of period $7,516,000 $8,729,000
CONTACT: ThermoGenesis Corp.
         Web site:
         Contact: Investor Relations
         +1-916-858-5107, or

ThermoGenesis Corp. Logo

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs